Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab

Overview

Journal J Clin Med

Specialty General Medicine

Date 2018 Jan 11

PMID 29320468

Citations 20

Authors

Alessandra Chen

Nabilah Ali

Peter Boasberg

Allen S Ho

Affiliations

Soon will be listed here.

Abstract

Cutaneous squamous cell carcinomas (SCC) affecting the regions of the head and neck can be challenging to resect surgically and refractory to chemotherapy or radiation therapy. Consequently; the treatment of squamous cell carcinomas of the skin is a focus of current research. One such advancement is immunotherapy. Herein we describe clinical remission of invasive, poorly differentiated squamous cell carcinoma of the pre-auricular region with external auditory canal involvement using cetuximab, an epidermal growth factor receptor (EGFR) antibody; and nivolumab, a programmed death receptor-1 (PD-1) antibody. Such durable and comprehensive disease resolution demonstrates the therapeutic potential of cetuximab and nivolumab in surgically challenging, treatment-resistant cutaneous squamous cell carcinoma.

Citing Articles

Case report: Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma.

Morecroft R, Phillipps J, Zhou A, Butt O, Khaddour K, Johanns T Front Oncol. 2024; 14:1385094.

PMID: 38779101 PMC: 11109434. DOI: 10.3389/fonc.2024.1385094.

Metastatic patterns and treatment options for head and neck cutaneous squamous cell carcinoma (Review).

Iancu D, Fulga A, Vesa D, Zenovia A, Fulga I, Sarbu M Mol Clin Oncol. 2024; 20(6):40.

PMID: 38756868 PMC: 11097132. DOI: 10.3892/mco.2024.2739.

Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.

Lai F, Clarke R, Cooper P, Stokes J, Calvert P Case Rep Oncol. 2023; 16(1):1156-1165.

PMID: 37900839 PMC: 10601823. DOI: 10.1159/000533759.

Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review.

Tamimi A, Tamimi A, Sorkheh F, Asl S, Ghafari A, Karimi A Cancer Rep (Hoboken). 2023; 6(5):e1802.

PMID: 37042307 PMC: 10172176. DOI: 10.1002/cnr2.1802.

Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma.

Shi M, Huang J, Sun Y Curr Med Sci. 2023; 43(2):213-222.

PMID: 36971976 DOI: 10.1007/s11596-023-2700-2.

References

Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S . Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. J Thorac Oncol. 2015; 10(6):910-23. DOI: 10.1097/JTO.0000000000000500. View

Stevenson M, Wang C, Abikhair M, Roudiani N, Felsen D, Krueger J . Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab. JAMA Dermatol. 2017; 153(4):299-303. DOI: 10.1001/jamadermatol.2016.5118. View

Ravulapati S, Leung C, Poddar N, Tu Y . Immunotherapy in Squamous Cell Skin Carcinoma: A Game Changer?. Am J Med. 2017; 130(5):e207-e208. DOI: 10.1016/j.amjmed.2016.12.020. View

Degache E, Crochet J, Simon N, Tardieu M, Trabelsi S, Moncourier M . Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2017; 32(7):e257-e258. DOI: 10.1111/jdv.14371. View

Chang A, Kim J, Luciano R, Sullivan-Chang L, Colevas A . A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor. JAMA Dermatol. 2015; 152(1):106-8. DOI: 10.1001/jamadermatol.2015.2705. View

Borradori L, Sutton B, Shayesteh P, Daniels G . Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. Br J Dermatol. 2016; 175(6):1382-1386. DOI: 10.1111/bjd.14642. View

Pickering C, Zhou J, Lee J, Drummond J, Peng S, Saade R . Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014; 20(24):6582-92. PMC: 4367811. DOI: 10.1158/1078-0432.CCR-14-1768. View

Ribas A, Hu-Lieskovan S . What does PD-L1 positive or negative mean?. J Exp Med. 2016; 213(13):2835-2840. PMC: 5154949. DOI: 10.1084/jem.20161462. View

Uribe P, Gonzalez S . Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract. 2011; 207(6):337-42. DOI: 10.1016/j.prp.2011.03.002. View

10.

Karia P, Han J, Schmults C . Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013; 68(6):957-66. DOI: 10.1016/j.jaad.2012.11.037. View

11.

Falchook G, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I . Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016; 4:70. PMC: 5109769. DOI: 10.1186/s40425-016-0176-3. View

12.

Topalian S, Sznol M, Mcdermott D, Kluger H, Carvajal R, Sharfman W . Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32(10):1020-30. PMC: 4811023. DOI: 10.1200/JCO.2013.53.0105. View

13.

Winkler J, Schneiderbauer R, Bender C, Sedlaczek O, Frohling S, Penzel R . Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br J Dermatol. 2016; 176(2):498-502. DOI: 10.1111/bjd.14664. View

14.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

15.

Li Y, Hanna G, Laga A, Haddad R, Lorch J, Hammerman P . Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res. 2015; 21(6):1447-56. PMC: 4359951. DOI: 10.1158/1078-0432.CCR-14-1773. View

16.

Kraus D, Carew J, Harrison L . Regional lymph node metastasis from cutaneous squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1998; 124(5):582-7. DOI: 10.1001/archotol.124.5.582. View

17.

Mullen J, Feng L, Xing Y, Mansfield P, Gershenwald J, Lee J . Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol. 2006; 13(7):902-9. DOI: 10.1245/ASO.2006.07.022. View

18.

Rogers H, Weinstock M, Harris A, Hinckley M, Feldman S, Fleischer A . Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010; 146(3):283-7. DOI: 10.1001/archdermatol.2010.19. View

19.

Ferris R, Lenz H, Trotta A, Garcia-Foncillas J, Schulten J, Audhuy F . Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2017; 63:48-60. PMC: 7505164. DOI: 10.1016/j.ctrv.2017.11.008. View

20.

Thompson A, Kelley B, Prokop L, Murad M, Baum C . Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis. JAMA Dermatol. 2016; 152(4):419-28. PMC: 4833641. DOI: 10.1001/jamadermatol.2015.4994. View